Cover Image
市場調查報告書

血栓性栓塞症:開發平台分析

Thromboembolism - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 200494
出版日期 內容資訊 英文 95 Pages
訂單完成後即時交付
價格
Back to Top
血栓性栓塞症:開發平台分析 Thromboembolism - Pipeline Review, H2 2017
出版日期: 2017年07月11日 內容資訊: 英文 95 Pages
簡介

血栓是在血液中損壞或移動稱為血栓性栓塞症。症狀為有熱的感覺、水腫、紅斑等,也有胸壁或腳上靜脈擴張(方面副靜脈)。危險因素有高血壓,真性糖尿病,抽煙,高膽固醇值等。治療用抗凝固劑、進行血栓溶解治療、手術等。

本報告提供血栓性栓塞症的治療藥開發平台的現狀及最新更新的各開發階段比較分析、企業和研究機關正在開發的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍

血栓性栓塞症 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業正在開發的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

  • AstraZeneca PLC
  • Bayer AG
  • Cereno Scientific AB
  • CSL Limited
  • 第一三共
  • Gamma Therapeutics, Inc.
  • Green Cross Corporation
  • Isis Pharmaceuticals, Inc.
  • Portola Pharmaceuticals, Inc.
  • Regado Biosciences, Inc.
  • Sanofi

治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AZ-12971554
  • betrixaban
  • C-3
  • CSL-3F7
  • edoxaban tosylate
  • Gammarin
  • GCC-2107
  • ISIS-FXIRx
  • Lysimab
  • Protein for Thromboembolism and Blood Coagulation
  • REG-2
  • rivaroxaban
  • semuloparin
  • Small Molecules to Inhibit HDAC for Thromboembolism
  • TAP-ANV
  • YG-001

最近的開發平台趨勢

暫停中的計劃

中止開發的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9499IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Pipeline Review, H2 2017, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.

When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thromboembolism - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thromboembolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 2, 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Thromboembolism - Overview
    • Thromboembolism - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Thromboembolism - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Thromboembolism - Companies Involved in Therapeutics Development
    • Bayer AG
    • China Biologic Products Inc
    • Daiichi Sankyo Company Ltd
    • F. Hoffmann-La Roche Ltd
    • Gamma Therapeutics Inc
    • GlycoMimetics Inc
    • Green Cross Corp
    • Ionis Pharmaceuticals Inc
    • Portola Pharmaceuticals Inc
    • Verseon Corp
  • Thromboembolism - Drug Profiles
    • antithrombin III (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • betrixaban - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • edoxaban tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gammarin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GCC-2107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GMI-1271 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IONIS-FXIRx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Lysimab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Thromboembolism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rivaroxaban - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAP-ANV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRX-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YG-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Thromboembolism - Dormant Projects
  • Thromboembolism - Discontinued Products
  • Thromboembolism - Product Development Milestones
    • Featured News & Press Releases
      • Jun 28, 2017: U.S. FDA Grants Priority Review of XARELTO (rivaroxaban) sNDA for a 10 mg Dose to Reduce the Risk of Recurrent Venous Thromboembolism
      • Jun 23, 2017: FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients
      • Apr 28, 2017: Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism
      • Mar 18, 2017: Bayer's Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study
      • Mar 13, 2017: Daiichi Sankyo Announces Large-scale Registry of Venous Thromboembolism in Cancer Patients
      • Mar 07, 2017: Portola Pharmaceuticals Announces Betrixaban Presentations at ACC.17
      • Mar 06, 2017: EINSTEIN CHOICE Study with Bayer's Rivaroxaban Accepted for Late-Breaking Clinical Trial Presentation at ACC.17
      • Feb 08, 2017: FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee Meeting
      • Dec 23, 2016: Portola Pharmaceuticals Announces FDA Accepts New Drug Application for Priority Review and EMA Validates Marketing Authorization Application for Oral, Factor Xa Inhibitor Anticoagulant Betrixaban
      • Dec 08, 2016: Daiichi Sankyo Announces Initiation of Real-World Study in LIXIANA (edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in NVAF and VTE
      • Dec 06, 2016: New Analysis Shows People with Cancer Who Received XARELTO (rivaroxaban) for Blood Clots Had Fewer ER Visits and Lower Healthcare Costs than Those Given Standard Treatment
      • Dec 06, 2016: ASH 2016: Explaining the lower bleeding risk of Verseon's anticoagulants
      • Nov 28, 2016: Portola Pharmaceuticals Announces Betrixaban Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition
      • Nov 28, 2016: Ten Abstracts on the Use of Bayer's Xarelto in Different Patient Populations Accepted for Presentation at ASH 2016
      • Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon's New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Thromboembolism, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Thromboembolism - Pipeline by Bayer AG, H2 2017
  • Thromboembolism - Pipeline by China Biologic Products Inc, H2 2017
  • Thromboembolism - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
  • Thromboembolism - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Thromboembolism - Pipeline by Gamma Therapeutics Inc, H2 2017
  • Thromboembolism - Pipeline by GlycoMimetics Inc, H2 2017
  • Thromboembolism - Pipeline by Green Cross Corp, H2 2017
  • Thromboembolism - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
  • Thromboembolism - Pipeline by Portola Pharmaceuticals Inc, H2 2017
  • Thromboembolism - Pipeline by Verseon Corp, H2 2017
  • Thromboembolism - Dormant Projects, H2 2017
  • Thromboembolism - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Thromboembolism, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top